Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587990 · ClinicalTrials.gov registry record · Phase 1
Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)
A Phase 1 study, sponsored by Joshua M Hare.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00587990 is a Phase 1 study that was terminated before completion, run by Joshua M Hare. The registered enrollment target is 9 participants.
The verdict
NCT00587990, a Phase 1 study, was terminated before completion, sponsored by Joshua M Hare.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Heart attacks are a leading cause of death in both men and women in the United States. When a person has a heart attack, blood is unable to reach a certain area of the heart, and if the blood supply is not re-established quickly, that area of the heart can suffer permanent damage. While recovery from a heart attack can be managed through medications and lifestyle changes, these treatments can not reverse the original damage to the heart. Current research is focusing on the development of cell-based therapies using stem cells to repair organs that have been irreversibly damaged by disease. A specific form of stem cells, called adult mesenchymal stem cells (MSCs), has shown promise for heart repair. This study will evaluate the safety and effectiveness of injecting MSCs into the heart to repair and restore heart function in people who have had a heart attack and who are having heart surgery for coronary artery bypass grafting (CABG).
Interventions
- GENETIC Placebo
- BIOLOGICAL Lower dose mesenchymal stem cell (MSC) injection
- BIOLOGICAL Higher dose MSC injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00587990
The ClinicalTrials.gov registry entry for NCT00587990 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joshua M Hare, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00587990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00587990 about?
NCT00587990 is a clinical study titled "Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)". Heart attacks are a leading cause of death in both men and women in the United States. When a person has a heart attack, blood is unable to reach a certain area of the heart, and if the blood supply is not re-established quickly, that area of the heart can suffer permanent damage. While recovery fro...
What is the current status of trial NCT00587990?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2007-11. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00587990?
The interventions under investigation include: Placebo (GENETIC), Lower dose mesenchymal stem cell (MSC) injection (BIOLOGICAL), Higher dose MSC injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT00587990?
This trial is sponsored by Joshua M Hare, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.